

1 **Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1**
2 **and skeletal muscle mass in chronic liver disease rats and humans.**

3 Yasuyuki Tamai^{1#}, Akiko Eguchi^{1#}, Ryuta Shigefuku¹, Hiroshi Kitamura², Mina Tempaku¹,
4 Ryosuke Sugimoto¹, Yoshinao Kobayashi³, Motoh Iwasa¹, Yoshiyuki Takei¹ and Hayato
5 Nakagawa¹

6
7 ¹Department of Gastroenterology and Hepatology, Mie University Graduate School of
8 Medicine, ²Department of Veterinary Medicine, School of Veterinary Medicine, Rakuno
9 Gakuen University, ³Center for Physical and mental health, Mie University Graduate School
10 of Medicine

11 # Equal contributed first author

12
13 **Address for correspondence:** Dr. Akiko Eguchi

14 Department of Gastroenterology and Hepatology, Mie University Graduate School of
15 Medicine

16 2-174 Edobashi, Tsu, Mie, 514-8507, Japan

17 Tel: +81-59-231-9238

18 Email: akieguchi@med.mie-u.ac.jp

19

20 **Running title: LCA effects on skeletal muscle hypertrophy**

21

22 **Funding:** This research was supported by JSPS KAKENHI Grant Number 22K08011 and
23 21H02892, and AMED under Grant Number JP21fk0210090 and JP22fk0210115.

24

25 **Conflict of Interest:** The authors state no conflict of interest.

26

27 **Key words:** chronic liver diseases, low muscle mass, skeletal muscle, bile acids, lithocholic
28 acid, liver-muscle axis.

29

30 **Abbreviation:** CLD; chronic liver disease, LCA; lithocholic acid, TGR5; G-protein-coupled
31 receptor 5, BA; bile acid, BCAA; branched-amino acid, PMI; psoas muscle area index, IGF;
32 insulin growth factor, mTOR; mammalian target of rapamycin; SMI, skeletal muscle index,
33 CA; cholic acid, CDCA; chenodeoxycholic acid, DCA; deoxycholic acid, MHC; myosin heavy
34 chain.

35

36

37 **Abstract**

38 [Background & aims] Hepatic sarcopenia is one of many complications associated with
39 chronic liver disease (CLD) and has a high mortality rate, however, the liver-muscle axis is
40 not fully understood. Therefore, few effective treatments exist for hepatic sarcopenia, the best
41 of which being branched-amino acid (BCAA) supplementation to help increase muscle mass.
42 Our aim was to investigate the molecular mechanism(s) of hepatic sarcopenia focused on
43 bile acid (BA) composition. [Methods] Gastrocnemius muscle phenotype and serum BA
44 levels were assessed in CLD rats treated with BCAA. Mouse skeletal muscle cells (C2C12)
45 were incubated with lithocholic acid (LCA), G-protein-coupled receptor 5 (TGR5) agonist or
46 TGR5 antagonist to assess skeletal muscle hypertrophy. The correlation between serum BA
47 levels and psoas muscle area index (PMI) was examined in 73 CLD patients. [Results]
48 Gastrocnemius muscle weight significantly increased in CLD rats treated with BCAA via
49 suppression of protein degradation pathways, coupled with a significant increase in serum
50 LCA levels. LCA treated C2C12 hypertrophy occurred in a concentration-dependent manner
51 linked with TGR5-Akt pathways based upon inhibition results via a TGR5 antagonist. In
52 human CLD, serum LCA levels were the sole factor positively correlated with PMI and were
53 significantly decreased in both the low muscle mass group and the deceased group. Serum
54 LCA levels were also shown to predict patient survival. [Conclusion] Our results indicate
55 LCA-mediated skeletal muscle hypertrophy via activation of TGR5-IGF1-Akt signaling

56 pathways. In addition, serum LCA levels were associated with skeletal muscle mass in
57 cirrhotic rats, as well as CLD patients, and predicted overall patient survival. [Funding] This
58 research was supported by JSPS KAKENHI Grant Number 22K08011 and 21H02892, and
59 AMED under Grant Number JP21fk0210090 and JP22fk0210115.

60

61 **Introduction**

62 Hepatic sarcopenia differs from aging sarcopenia insofar as it is defined by a rapid decrease
63 in muscle mass and power. Hepatic sarcopenia is but one in the panoply of complications
64 associated with chronic liver diseases (CLD), in particular liver cirrhosis with its high mortality
65 (or low survival rate) and poor post-liver transplantation outcomes (Ebadi et al., 2019, Hara et
66 al., 2016). A variety of factors are altered in hepatic sarcopenia, including decreased serum
67 branched-chain amino acid (BCAA) levels (Tajiri and Shimizu, 2018), increased bile acids
68 (BAs) (Kobayashi et al., 2017), abnormal insulin growth factor-1 (IGF-1) and mammalian
69 target of rapamycin (mTOR) signaling pathways (Allen et al., 2021), increased reactive
70 oxygen species and increased inflammatory cytokines and myostatin expression (Ebadi et al.,
71 2019, Allen et al., 2021). BCAA supplementation has been shown to significantly improve
72 skeletal muscle index measurements (Ismail et al., 2022). In contrast, anti-myostatin
73 monoclonal neutralizing antibodies developed by several companies failed in clinical trials
74 targeted to treat Duchenne muscular dystrophy (Wagner, 2020). The molecular mechanisms

75 underpinning the muscle-liver axis involved in hepatic sarcopenia are not fully understood.
76 Therefore, the elucidation of molecular mechanisms and effective treatment designs are
77 required to prevent the progression of hepatic sarcopenia and to improve overall patient
78 prognosis.

79 CLD has a major impact on BA composition (Sauerbruch et al., 2021). BAs are amphipathic
80 steroid molecules synthesized from cholesterol and are categorized as being primary or
81 secondary. Primary BAs are synthesized and conjugated in hepatocytes and secreted into
82 the intestine. Most conjugated BAs undergo deconjugation and dehydration by intestinal
83 bacteria, resulting in the production of secondary BAs. BA pools containing a mix of primary
84 and secondary BAs are essential for solubilizing lipids and fat-soluble vitamins thus
85 promoting their absorption into the small intestine. In addition to their canonical function in
86 digestion, BAs are known to act as signaling molecules that regulate metabolic pathways,
87 such as glucose, lipid and energy homeostasis, through various receptors including
88 G-protein-coupled receptor 5 (TGR5), farnesoid X receptor and vitamin D receptor (Arab et
89 al., 2017). TGR5 activation induced by cholic acid (CA), chenodeoxycholic acid (CDCA),
90 deoxycholic acid (DCA) and lithocholic acid (LCA) as part of the overall BA composition is a
91 key event regulating skeletal muscle cells with the most potent endogenous ligand for TGR5
92 being LCA (Pols et al., 2011). Indeed, LCA, a secondary BA, induced TGR5 activation in
93 skeletal muscle and enhanced muscle mass hypertrophy in mice through an increase in

94 IGF-1, a known muscle hypertrophy-related gene (Sasaki et al., 2018). However, the role of
95 LCA in cirrhotic liver disease-related sarcopenia has not been fully clarified.

96 In this study, we investigate the interaction between BAs, including LCA, and skeletal
97 muscle mass, in CLD rats, as well as CLD patients, and explore the beneficial effect of LCA
98 on skeletal muscle hypertrophy.

99

100 **Results**

101 **Increased gastrocnemius muscle weight is associated with suppression of protein** 102 **degradation pathways and elevation of serum LCA levels in CLD rats treated with** 103 **BCAA.**

104 To investigate whether increased gastrocnemius muscle weight is associated with changes in
105 BA composition, we used a CLD rat model administered with carbontetrachloride (CCl₄) for
106 10 weeks (4 weeks to establish advanced fibrosis, or cirrhosis, and an additional 6 weeks to
107 treat with BCAA for attenuation of liver injury), which we have previously reported (Tamai et
108 al., 2021). The ratio of gastrocnemius muscle weight to total body weight was significantly
109 increased in CLD rats treated with BCAA (CLD+BCAA) compared to untreated CLD rats (p
110 <0.05) (Figure. 1A). The overall pathological condition of gastrocnemius muscle was similar
111 between CLD and CLD+BCAA rats (Figure. 1B). Moreover, in concordance with the
112 aforementioned gastrocnemius muscle mass results, gastrocnemius muscle gene expression

113 levels of protein degradation pathways including muscle RING finger 1 (MuRF1), muscle
114 atrophy F-box protein (MafBx), ubiquitin and E214KDa were notably increased in CLD rats
115 compared with normal rats (indicated as a broken line in the graphs) and MafBx mRNA levels
116 were significantly decreased in gastrocnemius muscle from CLD+BCAA rats ($p < 0.05$)
117 (Figure. 1C). The mRNA levels of the repair gene, transcription factor forkhead box O1
118 (FOXO1), were notably decreased in CLD rat gastrocnemius muscle samples, but expression
119 recovered in gastrocnemius muscle samples from CLD+BCAA rats (Figure. 1C). To explore
120 whether increased gastrocnemius muscle mass was associated with BA composition, we
121 measured serum BA levels in CLD and CLD+BCAA rats. Total BAs were dramatically
122 increased in CLD rats when compared to normal rats (indicated as a broken line in a graph)
123 and decreased in CLD+BCAA rats (Figure. 1D). In line with the total BA data, the ratio of CA,
124 CDCA and DCA increased in CLD rats and showed a decreasing trend in CLD+BCAA rats
125 (Figure. 1E). Notably, the ratio of LCA to total BAs was dramatically decreased in CLD rats
126 and was significantly increased in the CLD+BCAA rat group ($p < 0.05$) (Figure. 1E). These
127 results suggest that an increase in gastrocnemius muscle mass may be associated with
128 serum LCA levels.

129

130 **LCA enhances muscle cell hypertrophy through TGR5-IGF-1 pathway.**

131 We next examined the effect of LCA on hypertrophy of skeletal muscle cells using C2C12
132 myoblasts that differentiate rapidly forming myotubes. C2C12 myoblasts were culture for 3
133 days and approached confluence, then differentiated to myotubes using varying
134 concentrations of LCA (Figure. 2A). The hypertrophy of C2C12 myotubes was overtly altered
135 in a concentration-dependent manner based on assessment using myosin heavy chain
136 (MHC) staining (Figure. 2B). Corresponding to cell morphological changes, the length and
137 width of the cells were significantly increased in a concentration-dependent manner under
138 quantitative analyses (length, $p < 0.001$: 0 vs. 700 nM and 70 vs. 700 nM, $p < 0.01$: 0 and 70
139 nM) (width, $p < 0.001$: 0 vs. 70 or 700 nM and 70 vs. 700 nM) (Figure. 2C). Previous reports
140 have shown LCA to be one of the most potent endogenous ligands for TGR5 (Pols et al.,
141 2011) capable of inducing IGF-1, which is a known muscle hypertrophy gene (Sasaki et al.,
142 2018). In the present study, we found the levels of *Tgr5* mRNA to be significantly increased in
143 C2C12 myotubes treated with LCA ($p < 0.05$: 70 and 700 nM) (Figure. 2D). Moreover, C2C12
144 myotubes undergoing LCA-induced hypertrophy showed significantly elevated levels of *Igf-1*
145 mRNA (Figure. 2D).

146

147 **TGR5 agonist accelerates muscle cell hypertrophy through IGF-1 and Akt activation.**

148 To investigate whether LCA-induced TGR5-IGF-1 activation is attenuated by blocking the
149 TGR5 pathway, C2C12 myotubes were coincubated with LCA and TGR5 antagonist

150 (SBI-115). The mRNA levels of *Tgr5* and *Igf-1* were significantly decreased in C2C12
151 myotubes treated with LCA+SBI-115 compared to LCA alone ($p < 0.01$ and $p < 0.05$,
152 respectively) (Figure. 3A). LCA is the most potent endogenous ligand for TGR5, but also
153 cytotoxic (Pols et al., 2011), therefore, LCA alone may not be an appropriate therapeutic
154 target molecule. A TGR5 agonist (INT-777) has been generated and shown to be a useful
155 molecule for TGR5 activation (Pellicciari et al., 2009). To explore whether this TGR5 agonist
156 induces muscle cell hypertrophy, differentiated C2C12 myoblasts (myotubes) were incubated
157 with INT-777. INT-777 induced obvious muscle cell hypertrophy when assessed using MHC
158 staining (Figure. 3B). INT-777 also elevated the mRNA levels of *Tgr5* and *Igf1* ($p < 0.01$ and $p <$
159 0.001 , respectively) (Figure. 3C). IGF-1 is known to activate the PI3K-Akt pathway, thus
160 leading to stimulation of protein synthesis, resulting in accelerated muscle hypertrophy
161 (Sartori et al., 2021). Indeed, the ratio of Akt phosphorylation against to total Akt was
162 significantly increased in C2C12 myotubes treated with INT-777 (Figure. 3D). These results
163 suggest that the TGR5-IGF-1-Akt3 pathway contributes to muscle hypertrophy.

164

165 **Serum LCA levels are positively and significantly correlated with PMI in CLD patients.**

166 The clinical features of the 73 (58 men and 15 women) enrolled CLD patients are shown in
167 Table 1. The cohort of patients admitted to our study was based on a variety of causative
168 agents: 13 hepatitis B virus (HBV), 21 hepatitis C virus (HCV), 21 nonalcoholic steatohepatitis

169 (NASH), 16 alcoholism and 2 other factors. Patients infected with HBV or HCV were under
170 infection control, with sustained virological response monitoring, by direct-acting antiviral
171 treatment against HCV, or treatment with nucleos(t)ide analogs against HBV in the clinical
172 course of each patient. The Barcelona Clinic Liver Cancer (BCLC) staging showed 11, 29, 13,
173 19 and 1 patients in Stage 0, A, B, C, and D, respectively.

174 The patient mean of total serum BAs was 18.3 ± 17.0 $\mu\text{mol/L}$, composed of primary BAs (12.7
175 ± 14.0 $\mu\text{mol/L}$) and secondary BAs (5.58 ± 7.91 $\mu\text{mol/L}$). The serum level of 15 individual BA
176 compositions are shown in Table 2. Total serum primary BA level was negatively correlated
177 with albumin ($r = -0.456$, $p < 0.0001$) and prothrombin time (PT, %) ($r = -0.410$, $p < 0.001$) and
178 was positively correlated with alkaline phosphatase (ALP) ($r = 0.240$, $p < 0.05$) (Figure. 4A).

179 Furthermore, the total primary BA level was significantly higher in albumin-bilirubin (ALBI)
180 grade 2 and 3 than in ALBI grade 1 ($p < 0.001$) (Figure. 4B). Notably, psoas muscle area
181 index (PMI) values were positively and significantly correlated with serum LCA levels (r
182 $= 0.304$, $p < 0.01$) and serum LCA ratio, which was LCA/total BAs ($r = 0.230$, $p < 0.05$), and the
183 only BA composition correlated with PMI (Figure. 4C). Next, we set out to assess the
184 changes in serum BA composition associated with muscle mass. To do this the cohort was
185 divided into two groups: low muscle mass, defined by PMI below $6.36 \text{ cm}^2/\text{m}^2$ for men and
186 $3.92 \text{ cm}^2/\text{m}^2$ for women (Hamaguchi et al., 2016), and normal muscle mass. The level of total
187 primary BAs was decreased and total secondary BAs was increased in the low muscle mass

188 group compared with the normal muscle mass group (Figure. 4D). The level of serum TGR5
189 ligands, CA, CDCA, DCA and LCA were also decreased in the low muscle mass group
190 (Figure. 4D). In particular, the level of serum LCA was significantly decreased in the low
191 muscle mass group (Figure. 4D). These results show that serum LCA levels are indicative of
192 overall muscle mass in CLD patients.

193

194 **Serum LCA levels may be a prognostic factor for survival.**

195 Finally, we investigated the association between serum BA composition levels and survival.

196 23 out of 73 patients (31.5 %) died in the average follow-up period of 1005 ± 471 days

197 following our study period. Serum total primary BA levels were significantly elevated in the

198 deceased group ($p < 0.05$), while serum LCA levels were significantly decreased in the

199 deceased group compared to the survival group ($p < 0.05$) (Figure. 5A). ROC analyses

200 concerning predictors of survival yielded AUC values of 0.670 (95% confidence interval:

201 0.542-0.797) ($p < 0.05$) for total primary BAs and 0.649 (95% confidence interval:

202 0.519-0.779) ($p < 0.05$) for LCA (Figure. 5B). In the present study, we calculated the ROC

203 analysis survival curve cut-off values for total primary BAs at $10.5 \mu\text{mol/L}$ (sensitivity 69.6%

204 and specificity 68.0%) and LCA at $0.32 \mu\text{mol/L}$ (sensitivity 73.9% and specificity 60%).

205 Patients with low total primary BAs (< 10.5) showed significantly better OS than patients with

206 high total primary BAs ($p < 0.01$) (Figure. 5C). Furthermore, patients with high LCA (≥ 0.32)

207 showed significantly improved OS than patients with low LCA ($p < 0.01$) (Figure. 5C). These
208 results suggest that serum LCA levels can be useful in predicting patient survival.

209

210 **Discussion**

211 In the present study, we demonstrated that serum LCA levels and LCA ratio were positively
212 associated with skeletal muscle mass in CLD rats treated with BCAA, as well as human
213 subjects, and that LCA-induced skeletal muscle cell hypertrophy occurs through
214 TGR5-IGF-1-Akt3 activation. BCAA supplementation is approved for use in CLD patients
215 within the clinical setting as a means to provide compensatory albumin thus maintaining liver
216 function (European Association for the Study of the Liver. Electronic address and European
217 Association for the Study of the, 2019), as well as increased muscle mass associated with an
218 acceleration of the TCA cycle (Ismail et al., 2022). In our previous study, we reported that
219 hepatocellular damage was attenuated using BCAA supplementation as a result of improved
220 lipid metabolism and mitochondrial damage repair in CLD rats (Tamai et al., 2021). Using the
221 same CLD rat model in the current study, we revealed that gastrocnemius muscle mass was
222 significantly increased using BCAA treatment. BCAA treatment has direct effects on liver and
223 skeletal muscle, however we hypothesized that one or more CLD-related molecules/factors
224 might regulate skeletal muscle mass via a liver-muscle axis. Indeed, we found that the serum
225 LCA ratio (LCA/total BAs) was significantly increased in CLD rats, which also showed an

226 increase in gastrocnemius muscle mass. Furthermore, we showed that serum LCA and LCA
227 ratio were significantly and positively associated with PMI in CLD patients. These results from
228 CLD rats and human subjects suggest that LCA can regulate muscle mass via a liver-muscle
229 axis, although further studies are warranted in the future using a greater number of patients
230 as part of a multicenter study.

231 The role of LCA in the progression of CLD has not been fully developed due to the lack of
232 general sensitivity in the system used to measure BA composition and is therefore not
233 sufficient to detect low levels of LCA in the blood. Our established highly-sensitive system for
234 BA composition (Murakami et al., 2018) allows us to detect all aspects of BA composition
235 resulting in the discovery of a new role for LCA, which is a positive correlation of serum BA
236 composition with skeletal muscle mass in CLD patients. Furthermore, we revealed that a
237 decrease in serum LCA level portends a worse survival outcome in CLD patients with
238 associated low muscle mass. CLD patients with sarcopenia, defined by low muscle mass and
239 power, also display decreased survival when compared to CLD patients without sarcopenia
240 (Hara et al., 2016), thus serum LCA may be a useful measure to monitor sarcopenia in CLD
241 patients. Current reports have also demonstrated that LCA is one of the most potent
242 anti-bacterial agents, selective against gram-positive bacteria, resulting in a longer lifespan of
243 centenarians (Sato et al., 2021) and is one of the most potent endogenous ligands for TGR5,
244 which protects against alcohol-induced liver steatosis and inflammation in mice

245 (Iracheta-Vellve et al., 2018). This evidence clearly shows that LCA plays a critical role in the
246 progression of CLD, and intestinal microbiota, as a function of the liver-gut axis. Our latest
247 results presented here, associating LCA with skeletal muscle mass, will lead to new insights
248 into the role of LCA as a component of the liver-muscle-gut axis.

249 In CLD rats and human subjects, we observed an association between gastrocnemius
250 muscle mass and LCA only, although serum CA, CDCA and DCA levels also showed a
251 decreasing trend in CLD patients with low muscle mass. This result is reasonable since the
252 hierarchy of BA affinity for TGR5 is as follows: LCA > DCA > CDCA > CA (Sato et al., 2007).
253 We also demonstrated that a TGR5 antagonist induced skeletal muscle cell hypertrophy
254 through IGF-1 activation, but we need further studies to develop a new antagonist with similar
255 affinity of LCA to the TGR5 binding pocket minus the cytotoxicity aspect.

256 In conclusion, we revealed new roles for LCA as a positive regulator of skeletal muscle
257 mass in both CLD rats and human patients, and as a mediator of skeletal muscle cell
258 hypertrophy in differentiated C2C12 myoblasts (myotubes). The serum LCA ratio
259 measurement was significantly decreased in CLD patients with low muscle mass. Current
260 results suggest that serum LCA levels may be used as a prognostic factor of survival in CLD
261 patients with sarcopenia, and a TGR5 agonist holds the potential to be a candidate as a
262 therapeutic target in the prevention of sarcopenia in CLD patients.

263

264 **Methods**

265 **Animal samples**

266 Our animal protocol (HKD43046) was reviewed and approved by the Institutional Animal
267 Care and Use Committee at Hokudo Co., Ltd (Sapporo, Japan). The rat model of CLD has
268 been previously described in detail (Tamai et al., 2021). Briefly, Wister male rats (SPF, CLEA
269 Japan: Tokyo, Japan) aged 7 weeks were fed solid normal diet, CE-2 (CLEA Japan), under
270 conventional conditions and were orally administered CCl₄ at 1.0 mL/kg twice a week for 4
271 weeks to induce advanced fibrosis, or cirrhosis, at which point the animals were divided into 2
272 groups by weight stratified random sampling. The CLD rats then received daily oral
273 administration of BCAA (10 g/kg/day) (n =10), or 0.9% saline solution (control) (n =10) for 6
274 weeks. The CLD state was maintained with twice weekly administration of CCl₄ at 0.5 mL/kg
275 for 6 weeks (10 weeks total). The rats were individually maintained at a constant temperature
276 (23 ± 3 °C), 50 ± 20% relative humidity and 12 h light–dark cycles (lights on at 7 am), and had
277 free access to food and water. Analysis of rat number was 9/10 in BCAA group and 8/10 in
278 control group due to death by CCl₄ in the experimental term. Wister male rats aged 10 weeks
279 were used as a control, wild-type rats (n=3).

280

281 **Gastrocnemius muscle histological analysis and serum BA measurement in rats**

282 All rats were sacrificed at the conclusion of our treatment protocol under anesthesia
283 (isoflurane, DS-pharma, Osaka, Japan). Whole rat blood was collected and allocated into
284 tubes with anticoagulant (EDTA). A portion of gastrocnemius muscle was fixed in 10%
285 formalin for 24 h and embedded in paraffin and the remaining gastrocnemius muscle was
286 flash frozen in liquid nitrogen and stored at -80°C. The gastrocnemius muscle sections were
287 prepared and stained for H&E (hematoxylin and eosin). All images were taken by Olympus
288 CKX53 (Olympus, Tokyo, Japan) and quantitated using Image J software (NIH Image).
289 Serum BA levels were quantified by LC-MS/MS at CMIC Pharma Science Co., Ltd. (Kobe,
290 Japan).

291

292 **Patients and serum BA measurements in human**

293 The study protocol (H2019-063) was approved by the Clinical Research Ethics Review
294 Committee of Mie University Hospital. This study was performed retrospectively on stored
295 samples, and subjects were allowed to opt out of their data being used. Written informed
296 consent was obtained from all subjects at the time of blood sampling. A total of 113
297 treatment-naïve patients with hepatocellular carcinoma (HCC) hospitalized in the Department
298 of Gastroenterology and Hepatology, Mie University Hospital for treatment of HCC between
299 January 2015 and January 2017 were included as a retrospective study. HCC diagnosis was
300 based on clinical history, serologic testing and radiologic imaging. 36 patients were excluded

301 due to oral administration of ursodeoxycholic acid. Three patients who had other
302 malignancies within the past 3 years were excluded. One patient was excluded due to kidney
303 transplant. As a result, a total of 73 patients with CLD were analyzed for the current study.
304 Patients positive for hepatitis B surface antigen were diagnosed with HBV infection, whereas
305 those positive for anti-HCV were diagnosed with HCV infection. Alcohol associated liver
306 disease was defined as alcohol consumption >60g/day. NASH was diagnosed based on
307 pathological findings and/or fatty liver without any other evident causes of chronic liver
308 diseases (viral, autoimmune, genetic, etc.). Hepatic functional reserve was categorized by
309 ALBI score (Johnson et al., 2015). The PMI [psoas muscle area at the middle of the third
310 lumbar vertebra (L3) (cm²)/height (m)²] was manually calculated from CT images. All
311 treatments were performed following the Japanese practical guidelines for HCC as possible
312 (Kokudo et al., 2019). Post-HCC treatment follow-up consisted of laboratory tests, including
313 tumor markers, every 3 months and dynamic CT or magnetic resonance imaging every 6
314 months.
315 BA concentrations were determined in a blind as described by Ando et al. with minor
316 modifications (Murakami et al., 2018, Ando et al., 2006). After the addition of internal
317 standards and 0.5 M potassium phosphate buffer (pH 7.4), BAs were extracted with Bond
318 Elut C18 cartridges and quantified by LC-MS/MS. Chromatographic separation was
319 performed using a Hypersil GOLD column (150 × 2.1 mm, 3.0 μm; Thermo Fisher Scientific)

320 at 40°C. The mobile phase consisted of (A) 20 mM ammonium acetate buffer (pH
321 7.5)-acetonitrile-methanol (70:15:15, v/v/v) and (B) 20 mM ammonium acetate buffer (pH
322 7.5)-acetonitrile-methanol (30:35:35, v/v/v). The following gradient program was used at a
323 flow rate of 200 µl/min: 0–100% B for 20 min, hold 100% B for 10 min, and re-equilibrate to
324 100% A for 8 min.

325

326 **Cell culture, treatment and immunofluorescence**

327 C2C12 myoblasts (kindly gift from Dr. Fujita at Tokyo institute of Technology) were
328 maintained in DMEM containing 20% FBS at 37 °C and 5% CO₂. The confluent cells were
329 differentiated into myotubes by culturing with DMEM containing 2% horse serum for 5 days
330 with LCA (Millipore-Sigma, Japan), TGR5 agonist (1 µM INT-777, Millipore-Sigma) or TGR5
331 agonist plus TGR5 antagonist (100 µM SBI-115, Millipore-Sigma). All experiments were
332 repeated twice with three biological replicates in each experiment. For immunofluorescence,
333 cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.5% Triton X-100
334 for 5min and then incubated with anti-MHC antibody (#376157, Santa Cruz, Dallas, TX) at 4
335 °C overnight. MHC and nucleus were visualized with Alexa 488-conjugated anti-mouse
336 antibody and DAPI, respectively. All pictures were taken by KEENC BZ-X710 (KEYENCE,
337 Japan). Changes in cell strength and width were quantified using NIH ImageJ software.

338

339 **Gene expression**

340 Total RNA was isolated from gastrocnemius muscle or C2C12 cells using TRI Reagent
341 (Molecular Research Center, Cincinnati, OH) according to the manufacturer's instructions.
342 The cDNA was synthesized from total RNA using a cDNA Synthesis kit (Takara, Shiga,
343 Japan). Real-time PCR quantification was performed using the KAPA SYBR FAST qPCR
344 master mix (KAPA Biosystems, Wilmington, MA) or a TaqMan gene expression assay
345 (Thermo Fisher Scientific Inc.) for *Sod1*, and the 7300 Real-Time PCR Detection System
346 (Thermo Fisher Scientific Inc.). The PCR primers were used to amplify each gene as listed in
347 Supplemental Table 1. Mean values of mRNA were normalized to *beta 2 microglobulin*
348 (*B2m*).

349

350 **Western Blotting Analysis**

351 C2C12 cells were homogenized in RIPA buffer (150 mM NaCl, 1.0% NP-40, 1% sodium
352 deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris-HCl pH8.0) containing a protease
353 inhibitor cocktail (Millipore-Sigma) and phosphatase inhibitors (Millipore-Sigma). 20 µg of cell
354 lysate was resolved using a TGX gel (Bio-Rad, Hercules, CA), transferred to
355 a polyvinylidenedifluoride membrane, and blotted with the appropriate primary antibody.
356 Membranes were incubated with peroxidase-conjugated secondary antibody (GE Healthcare
357 Bioscience, Marlborough, MA). Protein bands were visualized using an

358 enhanced chemiluminescence reagent (Bio-Rad), digitized using a Lumino-image analyzer
359 (LAS-4000 iniEPUV, Fuji Film, Tokyo, Japan), and quantitated using the program Multi
360 Gauge (Fuji Film). Anti-GAPDH (#60004, Proteintech, Rosemont, IL), anti-phospho-Akt (Ser
361 473) (#4060, Cell Signaling Technology, Danvers, MA) and anti-pan-Akt (#4691, Cell
362 Signaling Technology) were used as primary antibodies.

363

364 **Statistical analyses**

365 Continuous variables are presented as mean \pm standard deviation or median
366 (minimum-maximum), and categorical variables are shown as numbers of patients. The
367 continuous data were compared using the Mann-Whitney U or unpaired t test in two groups or
368 Kruskal-Wallis in multiple groups. The relationship between the serum BA levels and clinical
369 data were examined using Spearman's rank correlation coefficient. The categorical data were
370 compared using the Chi-squared test. Receiver operator characteristic (ROC) curves and the
371 corresponding area under the curve (AUC) were used to obtain cut-offs for the outcomes.
372 The Youden index was applied to calculate the optimal cut-off point. Overall survival (OS)
373 was measured using the Kaplan-Meier method and compared using the log-rank test. All
374 statistical analyses were performed using SPSS23.0 software (IBM, Armonk, NY) or Prism 9
375 (GraphPad Software, Inc., CA, USA). Differences were considered to be significant at p
376 <0.05.

377

378 **Acknowledgement**

379 We would like to thank Dr. Teruo Miyazaki, Dr. Akira Honda and Dr. Tadashi Ikegami in

380 Department of Gastroenterology, Tokyo Medical University Ibaraki medical center for

381 measurement of human BAs.

382

383 **References**

384 ALLEN, S. L., QUINLAN, J. I., DHALIWAL, A., ARMSTRONG, M. J., ELSHARKAWY, A. M.,
385 GREIG, C. A., LORD, J. M., LAVERY, G. G. & BREEN, L. 2021. Sarcopenia in chronic
386 liver disease: mechanisms and countermeasures. *Am J Physiol Gastrointest Liver*
387 *Physiol*, 320, G241-G257.

388 ANDO, M., KANEKO, T., WATANABE, R., KIKUCHI, S., GOTO, T., IIDA, T., HISHINUMA, T.,
389 MANO, N. & GOTO, J. 2006. High sensitive analysis of rat serum bile acids by liquid
390 chromatography/electrospray ionization tandem mass spectrometry. *J Pharm Biomed*
391 *Anal*, 40, 1179-86.

392 ARAB, J. P., KARPEN, S. J., DAWSON, P. A., ARRESE, M. & TRAUNER, M. 2017. Bile acids
393 and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
394 *Hepatology*, 65, 350-362.

395 EBADI, M., BHANJI, R. A., MAZURAK, V. C. & MONTANO-LOZA, A. J. 2019. Sarcopenia in
396 cirrhosis: from pathogenesis to interventions. *J Gastroenterol*, 54, 845-859.

397 EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. ELECTRONIC ADDRESS,
398 E. E. E. & EUROPEAN ASSOCIATION FOR THE STUDY OF THE, L. 2019. EASL
399 Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol*, 70,
400 172-193.

401 HAMAGUCHI, Y., KAIDO, T., OKUMURA, S., KOBAYASHI, A., HAMMAD, A., TAMAI, Y.,
402 INAGAKI, N. & UEMOTO, S. 2016. Proposal for new diagnostic criteria for low
403 skeletal muscle mass based on computed tomography imaging in Asian adults.
404 *Nutrition*, 32, 1200-5.

405 HARA, N., IWASA, M., SUGIMOTO, R., MIFUJI-MOROKA, R., YOSHIKAWA, K.,
406 TERASAKA, E., HATTORI, A., ISHIDOME, M., KOBAYASHI, Y., HASEGAWA, H.,
407 IWATA, K. & TAKEI, Y. 2016. Sarcopenia and Sarcopenic Obesity Are Prognostic
408 Factors for Overall Survival in Patients with Cirrhosis. *Intern Med*, 55, 863-70.

409 IRACHETA-VELLVE, A., CALENDIA, C. D., PETRASEK, J., AMBADE, A., KODYS, K.,
410 ADORINI, L. & SZABO, G. 2018. FXR and TGR5 Agonists Ameliorate Liver Injury,
411 Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice.

412 *Hepatol Commun*, 2, 1379-1391.

413 ISMAIEL, A., BUCSA, C., FARCAS, A., LEUCUTA, D. C., POPA, S. L. & DUMITRASCU, D. L.
414 2022. Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia
415 in Liver Cirrhosis: Systematic Review and Meta-Analysis. *Front Nutr*, 9, 749969.

416 JOHNSON, P. J., BERHANE, S., KAGEBAYASHI, C., SATOMURA, S., TENG, M., REEVES,
417 H. L., O'BEIRNE, J., FOX, R., SKOWRONSKA, A., PALMER, D., YEO, W., MO, F.,
418 LAI, P., INARRAIRAEGUI, M., CHAN, S. L., SANGRO, B., MIKSAD, R., TADA, T.,
419 KUMADA, T. & TOYODA, H. 2015. Assessment of liver function in patients with
420 hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. *J Clin*
421 *Oncol*, 33, 550-8.

422 KOBAYASHI, Y., HARA, N., SUGIMOTO, R., MIFUJI-MOROKA, R., TANAKA, H., EGUCHI,
423 A., IWASA, M., HASEGAWA, H., IWATA, K., TAKEI, Y. & TAGUCHI, O. 2017. The
424 Associations between Circulating Bile Acids and the Muscle Volume in Patients with
425 Non-alcoholic Fatty Liver Disease (NAFLD). *Intern Med*, 56, 755-762.

426 KOKUDO, N., TAKEMURA, N., HASEGAWA, K., TAKAYAMA, T., KUBO, S., SHIMADA, M.,
427 NAGANO, H., HATANO, E., IZUMI, N., KANEKO, S., KUDO, M., IIJIMA, H., GENDA,
428 T., TATEISHI, R., TORIMURA, T., IGAKI, H., KOBAYASHI, S., SAKURAI, H.,
429 MURAKAMI, T., WATADANI, T. & MATSUYAMA, Y. 2019. Clinical practice guidelines
430 for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC
431 guidelines) 2019 update. *Hepatol Res*, 49, 1109-1113.

432 MURAKAMI, M., IWAMOTO, J., HONDA, A., TSUJI, T., TAMAMUSHI, M., UEDA, H.,
433 MONMA, T., KONISHI, N., YARA, S., HIRAYAMA, T., MIYAZAKI, T., SAITO, Y.,
434 IKEGAMI, T. & MATSUZAKI, Y. 2018. Detection of Gut Dysbiosis due to Reduced
435 Clostridium Subcluster XIVa Using the Fecal or Serum Bile Acid Profile. *Inflamm*
436 *Bowel Dis*, 24, 1035-1044.

437 PELLICCIARI, R., GIOIELLO, A., MACCHIARULO, A., THOMAS, C., ROSATELLI, E.,
438 NATALINI, B., SARDELLA, R., PRUZANSKI, M., RODA, A., PASTORINI, E.,
439 SCHOONJANS, K. & AUWERX, J. 2009. Discovery of
440 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective
441 agonist for the TGR5 receptor, a novel target for diabetes. *J Med Chem*, 52, 7958-61.

442 POLS, T. W., NORIEGA, L. G., NOMURA, M., AUWERX, J. & SCHOONJANS, K. 2011. The
443 bile acid membrane receptor TGR5: a valuable metabolic target. *Dig Dis*, 29, 37-44.

444 SARTORI, R., ROMANELLO, V. & SANDRI, M. 2021. Mechanisms of muscle atrophy and
445 hypertrophy: implications in health and disease. *Nat Commun*, 12, 330.

446 SASAKI, T., KUBOYAMA, A., MITA, M., MURATA, S., SHIMIZU, M., INOUE, J., MORI, K. &
447 SATO, R. 2018. The exercise-inducible bile acid receptor Tgr5 improves skeletal
448 muscle function in mice. *J Biol Chem*, 293, 10322-10332.

449 SATO, H., GENET, C., STREHLE, A., THOMAS, C., LOBSTEIN, A., WAGNER, A.,

450 MIOSKOWSKI, C., AUWERX, J. & SALADIN, R. 2007. Anti-hyperglycemic activity of
451 a TGR5 agonist isolated from *Olea europaea*. *Biochem Biophys Res Commun*, 362,
452 793-8.

453 SATO, Y., ATARASHI, K., PLICHTA, D. R., ARAI, Y., SASAJIMA, S., KEARNEY, S. M., SUDA,
454 W., TAKESHITA, K., SASAKI, T., OKAMOTO, S., SKELLY, A. N., OKAMURA, Y.,
455 VLAMAKIS, H., LI, Y., TANOUE, T., TAKEI, H., NITTONO, H., NARUSHIMA, S., IRIE,
456 J., ITOH, H., MORIYA, K., SUGIURA, Y., SUEMATSU, M., MORITOKI, N., SHIBATA,
457 S., LITTMAN, D. R., FISCHBACH, M. A., UWAMINO, Y., INOUE, T., HONDA, A.,
458 HATTORI, M., MURAI, T., XAVIER, R. J., HIROSE, N. & HONDA, K. 2021. Novel bile
459 acid biosynthetic pathways are enriched in the microbiome of centenarians. *Nature*,
460 599, 458-464.

461 SAUERBRUCH, T., HENNENBERG, M., TREBICKA, J. & BEUERS, U. 2021. Bile Acids,
462 Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. *Front Physiol*, 12, 718783.

463 TAJIRI, K. & SHIMIZU, Y. 2018. Branched-chain amino acids in liver diseases. *Transl*
464 *Gastroenterol Hepatol*, 3, 47.

465 TAMAI, Y., CHEN, Z., WU, Y., OKABE, J., KOBAYASHI, Y., CHIBA, H., HUI, S. P., EGUCHI,
466 A., IWASA, M., ITO, M. & TAKEI, Y. 2021. Branched-chain amino acids and l-carnitine
467 attenuate lipotoxic hepatocellular damage in rat cirrhotic liver. *Biomed Pharmacother*,
468 135, 111181.

469 WAGNER, K. R. 2020. The elusive promise of myostatin inhibition for muscular dystrophy.
470 *Curr Opin Neurol*, 33, 621-628.

471

472 **Figure legends**

473 **Figure 1. Gastrocnemius muscle mass and serum LCA ratio are significantly increased**

474 **in CLD rats treated with BCAA.** (A) Changes in gastrocnemius muscle/body weight in CLD

475 rats (n=9) and CLD rats treated with BCAA (CLD+BCAA)(n=8). (B) Hematoxylin & Eosin

476 (H&E) staining in gastrocnemius muscle sections from CLD and CLD+BCAA rats. Scale bar,

477 50 μ m. (C) Gene expression of *MuRF1*, *MafBx*, *ubiquitin*, *E214KDa* and *FOXO1* in

478 gastrocnemius muscle from CLD and CLD+BCAA rats as measured by qPCR. All gene

479 expression levels were normalized to housekeeping control, *β 2 microglobulin*, and shown

480 relative to the expression levels of control (normal rats). Broken line indicates the expression
481 levels of gastrocnemius muscle from normal rats. (D, E) Changes in (C) serum total BAs, (D)
482 CA/total BAs, CDCA/total BAs, DCA/total BAs and LCA/total BAs in CLD and CLD+BCAA
483 rats. Broken line indicates the serum BA levels from normal rats.*p<0.05. Values are mean ±
484 SEM. CLD; chronic liver disease, MuRF1; muscle RING finger 1, MafBx; muscle atrophy
485 F-box protein, FOXO1; forkhead box O1, BAs; bile acids, CA; cholic acid, CDCA;
486 chenodeoxycholic acid, DCA; deoxycholic acid, LCA; lithocholic acid.

487

488 **Figure 2. LCA induces hypertrophy of skeletal muscle cells.** (A) Scheme of experimental
489 design in C2C12 myoblast to myotubes treated with LCA. (B) Myosin heavy chain (MHC)
490 staining in C2C12 myotubes treated with 0, 70 and 700 nM of LCA. Scale bar, 50 µm. (C)
491 Changes in length and width of MHC positive cells quantified from Figure 2B. (D) Gene
492 expression of *Tgr5* and *Igf-1* in C2C12 myotubes treated with 0, 70 and 700 nM of LCA.
493 ****p<0.0001, **p<0.01, *p<0.05. Values are mean ± SEM from three biological replicates.
494 LCA; lithocholic acid, TGR5; G-protein-coupled receptor 5, IGF; insulin growth factor.

495

496 **Figure 3. Hypertrophy of skeletal muscle cells is induced by TGR5-IGF-1-Akt3**
497 **activation.** (A) Gene expression of *Tgr5* and *Igf-1* in C2C12 myotubes treated with 70 nM
498 LCA and 70 nM LCA plus 100 µM of TGR5 antagonist, SBI-115. (B) Myosin heavy chain

499 (MHC) staining in C2C12 myotubes treated with 1 μ M of TGR5 agonist, INT-777. Scale bar,
500 50 μ m. (C) Gene expression of *Tgr5* and *Igf-1* in C2C12 myotubes treated with 1 μ M of
501 INT-777. (D) Protein expression of phosphorylated Akt3 (p-Akt3), Akt3 and GAPDH
502 measured by western blotting in C2C12 myotubes treated with 1 μ M of INT-777.
503 Quantification of pAkt3/Akt3 from western blotting membrane. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$.
504 Values are mean \pm SEM from three biological replicates. LCA; lithocholic acid, TGR5;
505 G-protein-coupled receptor 5, IGF; insulin growth factor; Akt3; AKT serine/threonine kinase 3,
506 GAPDH; glyceraldehyde-3-phosphate dehydrogenase.

507

508 **Figure 4. Serum LCA level is significantly and positively correlated with PMI in CLD**
509 **patients and is significantly decreased in CLD patients with low muscle mass. (A)**

510 Correlation between total primary BAs and Albumin (ALB), alkaline phosphatase (ALP) or
511 prothrombin time (PT) (%) in CLD patients. (B) Changes in total primary BAs in CLD patients
512 with ALBI grade 1 or grade 2-3. (C) Correlation of Psoas muscle mass index (PMI) with
513 serum LCA and LCA ratio in CLD patients. (D) Changes in total serum primary BAs, total
514 secondary BAs, CA, CDCA, DCA and LCA in CLD patients with normal muscle mass and low
515 muscle mass. *** $p < 0.001$, * $p < 0.05$. Values are mean \pm SEM. CLD; chronic liver disease,
516 BAs; bile acids, ALBI; albumin-bilirubin, CA; cholic acid, CDCA; chenodeoxycholic acid, DCA;
517 deoxycholic acid, LCA; lithocholic acid.

518

519 **Figure 5. Improved survival in CLD patients with high levels of serum LCA.** (A) Serum
520 total of primary BAs and LCA ratio in survival and deceased CLD patients. (B) ROC curve of
521 serum total or primary BAs and LCA. (C) CLD patient survival curve with total primary BAs
522 and LCA. Correlation of Psoas muscle mass index (PMI) with serum LCA and LCA ratio in
523 CLD patients. * $p < 0.05$. Values are mean \pm SEM. BAs; bile acids, LCA; lithocholic acid, AUC;
524 area under the curve.

525

526 **Figure 1-source data.** Ratio of gastrocnemius weight/body weight in CLD rats and CLD rats
527 treated with BCAA (CLD+BCAA). Serum total BAs, CA/total BAs, CDCA/total BAs, DCA/total
528 BAs and LCA/total BAs in CLD and CLD+BCAA rats.

529 **Figure 2-source data.** Ratio of length and width of MHC positive cells quantified from myosin
530 heavy chain (MHC) staining in C2C12 myotubes treated with 0, 70 and 700 nM of LCA.

531 **Figure 3-source data.** Original membrane of immunoblotting.

532 **Figure 4-source data.** Serum total primary BAs, albumin (ALB), alkaline phosphatase (ALP),
533 prothrombin time (PT) (%), psoas muscle mass index (PMI), LCA and LCA ratio in CLD
534 patients. Serum total serum primary BAs, total secondary BAs, CA, CDCA, DCA and LCA in
535 CLD patients with normal muscle mass and low muscle mass.

536 **Figure 5-source data.** Serum total of primary BAs and LCA ratio in survival and deceased

537 CLD patients. CLD patient survival curve with total primary BAs and LCA.

538 **Table 1-source data.** Serum albumin, total bilirubin, ALBI, prothrombin time and PMI in CLD

539 patients.

540 **Table 2-source data.** Serum total BAs, total primary BAs, total secondary BAs and bile acids

541 composition in CLD patients.

542

543

544 **Table 1. CLD patient baseline clinical and biochemical profiles of CLD patients.**

	n=73
Age, years	71.0±11.0
Gender, male/female	58/15
Etiology, HBV/HCV/NASH/alcohol/others	13/21/21/16/2
BCLC (0/A/B/C/D)	11/29/13/19/1
Albumin, g/dl	4.04±0.49
Total bilirubin, mg/dl	1.00±0.53
ALBI	-2.65±0.48
Prothrombin time, %	87.6±18.7
PMI, cm ² /m ²	5.13±1.99

545 Data are presented as number of patients, mean ± standard deviation.

546 CLD; chronic liver disease, HBV; hepatitis B virus, HCV; hepatitis C virus, NASH;

547 nonalcoholic steato hepatitis, ALBI: The albumin-bilirubin, PMI: psoas mass index.

548

549 **Table 2. Baseline bile acids composition.**

	n=73 (mmol/L)
Total bile acids	18.3±17.0
Total of primary bile acids	12.7±14.0
CA	1.30±3.28
GCA	1.71±2.86
TCA	0.35±0.78
CDCA	2.68±4.78
GCDCA	4.69±5.64
TCDCA	1.95±4.03
Total of secondary bile acids	5.58±7.91
DCA	0.89±1.19
GDCA	0.99±1.88
TDCA	0.19±0.46
LCA	0.067±0.112
GLCA	0.020±0.048
TLCA	0.003±0.013
UDCA	1.13±2.38
GUDCA	2.21±5.56
TUDCA	0.07±0.24

550 Data are presented as number of patients, mean ± standard deviation.

551 CA: cholic acid, GCA: glycocholic acid, TCA: taurocholic acid, CDCA: chenodeoxycholic acid,

552 GCDCA: glycochenodeoxycholic acid, TCDCA: taurochenodeoxycholic acid, DCA:

553 deoxycholic acid, GDCA: glycodeoxycholic acid, TDCA: taurodeoxycholic acid, LCA:

554 lithocholic acid, GLCA: glycolithocholic acid, TLCA: tauroolithocholic acid, UDCA:

555 ursodeoxycholic acid, GUDCA: glyoursodeoxycholic acid, TUDCA: tauroursodeoxycholic


556 acid.

557


558

559


A




B




C








D




E









A



B



C



D




Figure 5 Tamai et al

